EyePoint, Inc. (EYPT) Latest Company News

Oct 19, 2026, 17:16 UTC
EyePoint is halting its wet age-related macular degeneration clinical trials early.
Source:
- benzinga.com
Oct 19, 2026, 17:16 UTC
EyePoint is cutting its workforce by 53% as it pivots its focus.
Source:
- benzinga.com
Oct 19, 2026, 16:47 UTC
EyePoint, Inc. shares fell 85.71% to $0.43 after its DURAVYU Phase 3 LUCIA trial failed to demonstrate statistical non-inferiority.
Source:
- s.kabutan.jp
Oct 19, 2026, 12:52 UTC
EyePoint, Inc. reported that the LUCIA Phase III trial of DURAVYU for wet age-related macular degeneration missed its primary endpoint, while key secondary endpoints were met; at week 56, 52% of participants needed no supplemental treatment and 71% needed zero or one supplemental treatment.
Source:
- finance.sina.cn
Oct 19, 2026, 11:15 UTC
EyePoint announced a strategic prioritization to reduce operating expenses and focus resources on its late-stage DURAVYU program for diabetic macular edema.
Source:
- globenewswire.com
Sep 16, 2026, 11:00 UTC
EyePoint, Inc. granted non-statutory stock options to a new employee as an inducement award outside its 2023 Long-Term Incentive Plan under NASDAQ Listing Rule 5635(c)(4).
Source:
- globenewswire.com
Aug 28, 2026, 23:10 UTC
Kessler Topaz Meltzer & Check LLP launched an investigation into EyePoint, Inc. for potential federal securities law violations on behalf of investors who suffered significant losses.
Source:
- prnewswire.com
Aug 14, 2026, 20:32 UTC
EyePoint, Inc. granted non-statutory stock options to new employees as inducement awards under NASDAQ Listing Rule 5635(c)(4).
Source:
- globenewswire.com
Aug 5, 2026, 11:00 UTC
EyePoint, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting $180 million in cash and investments as of that date.
Source:
- globenewswire.com

EYPT

EyePoint is halting its wet age-related macular degeneration clinical trials early.

EyePoint is cutting its workforce by 53% as it pivots its focus.

EyePoint, Inc. shares fell 85.71% to $0.43 after its DURAVYU Phase 3 LUCIA trial failed to demonstrate statistical non-inferiority.

EyePoint, Inc. reported that the LUCIA Phase III trial of DURAVYU for wet age-related macular degeneration missed its primary endpoint, while key secondary endpoints were met; at week 56, 52% of participants needed no supplemental treatment and 71% needed zero or one supplemental treatment.

EyePoint announced a strategic prioritization to reduce operating expenses and focus resources on its late-stage DURAVYU program for diabetic macular edema.

EyePoint, Inc. granted non-statutory stock options to a new employee as an inducement award outside its 2023 Long-Term Incentive Plan under NASDAQ Listing Rule 5635(c)(4).

Kessler Topaz Meltzer & Check LLP launched an investigation into EyePoint, Inc. for potential federal securities law violations on behalf of investors who suffered significant losses.

EyePoint, Inc. granted non-statutory stock options to new employees as inducement awards under NASDAQ Listing Rule 5635(c)(4).

EyePoint, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting $180 million in cash and investments as of that date.